Stocks DiaMedica Cuts Oppenheimer Target to $6 Due to Litigation Delay From Investing.comMarch 21, 2024 On Thursday, Oppenheimer adjusted his forecast for DiaMedica Therapeutics Inc. shares. (NASDAQ:DMAC), lowering its price…
